Interní Med. 2003; 5(2): 71-77

Nové směry a perspektivy v léčbě hematologických malignit

MUDr. Tomáš Papajík CSc, MUDr. Edgar Faber CSc, Karel Indrák
Hemato-onkologická klinika FN a LF UP v Olomouci

Keywords: imatinib, leukemia, lymphoma, monoclonal antibodie, rituximab, transplantation.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Papajík T, Faber E, Indrák K. Nové směry a perspektivy v léčbě hematologických malignit. Interní Med. 2003;5(2):71-77.

Moderní kombinovaná chemoterapie a zvláště vysoce dávkované režimy přinesly zlepšení výsledků léčby nádorů z krvetvorných buněk. U mnohých nemocných je však tato léčba provázena řadou časných i pozdních komplikací toxického charakteru díky působení na životně důležité tkáně a orgány. Snahou proto je vyvinout takové léčebné přístupy, které by měly pokud možno co nejcílenější efekt na populaci nádorových buněk a mohly by být použity u většiny nemocných. Hlavními představiteli nových léčebných metod v hemato-onkologii jsou monoklonální protilátky, imatinib mesylát a program alogenních transplantací po přípravných režimech se sníženou intenzitou. Tyto postupy řadě nemocných prodlužují kvalitní život bez známek recidivy onemocnění a u mnohých vedou k vyléčení.

NEW TRENDS AND PERSPECTIVES IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES

Modern cytotoxic therapy and high-dose chemotherapy have improved results and clinical management of hematologic malignancies. However this therapy is often associated with substantial early or late toxic complications due to lack of specificity for tumor cells which results in damage of normal tissues. The goal is to construct new therapeutic approaches with the target effect on population of neoplastic cells and with the possibility of administration in most of patients with certain type of leukemia or lymphoma. Monoclonal antibodies, imatinib mesylate and nonmyeloablative stem cell transplantation represent the main new therapeutic concepts in hemato-oncology. These approaches prolong disease free or progression free survival, improve quality of life and can even lead to cure a significant portion of patients.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anagnostopoulos A, Giralt S. Critical review on non-myeloablative stem cell transplantation (NST). Crit Rev Oncol Hematol 2002; 44: 175-190. Go to original source... Go to PubMed...
    2. Barret J, Childs R. Non-myeloablative stem cell transplants. Br J Haematol 2000; 111: 6-17. Go to original source... Go to PubMed...
    3. Bocchia M, Bronte V, Colombo MP, et al. Antitumor vaccination: where we stand. Haematologica 2000; 85: 1172-1206. Go to PubMed...
    4. Countouriotis A, Moore TB, Sakamoto KM. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells 2002; 20: 215-229. Go to original source... Go to PubMed...
    5. Champlin R, Khouri I, Shimoni A, et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18-29. Go to original source... Go to PubMed...
    6. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037. Go to original source... Go to PubMed...
    7. Faber E, Hluší A, Indrák K, et al. Imatinib (Glivec) v léčbě nemocných s akcelerovanou fází chronické myeloidní leukemie - první zkušenosti. Trendy v medicíně 2002; 4: 3-7.
    8. Feuring-Buske M, Buske C, Unterhalt M, Hiddemann W. Recent advances in antigen-targeted therapy in non-Hodgkin´s lymphoma. Ann Hematol 2000; 79: 167-174. Go to original source... Go to PubMed...
    9. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin´s lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol 2001; 39: 195-201. Go to original source... Go to PubMed...
    10. Jurcic JG. Antibody therapy for residual disease in acute myelogenous leukemia. Crit Rev Oncol Hematol 2001; 38: 37-45. Go to original source... Go to PubMed...
    11. Kantarjian H, Sawyers Ch, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346(9): 645-652. Go to original source... Go to PubMed...
    12. Larson RA. On behalf of the IRIS (International Randomized INF vs STI571 Study Group): Imatinib (STI571, GleevecTM) as initial therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia (CML): Results of a randomized phase III study vs interferon-alfa + cytarabine (INF+AraC). Blood 2002; 100: 4(a).
    13. McCarthy NJ, Bishop MR. Nonmyeloablative allogeneic stem cell transplantation: early promise and limitations. Oncologist 2000; 5: 487-496. Go to original source... Go to PubMed...
    14. McLaughlin P. Rituximab: perspective on single agent experience, and future directions in combination trials. Crit Rev Oncol Hematol 2001; 40: 3-16. Go to original source... Go to PubMed...
    15. Sawyers Ch, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase 2 study. Blood 2002; 99: 3530-3539. Go to original source... Go to PubMed...
    16. Spitzer TR. Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism. Oncologist 2000; 5: 215-223. Go to original source... Go to PubMed...
    17. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of phase 2 study. Blood 2002; 99(6): 1928-1937. Go to original source... Go to PubMed...
    18. Tamm I, Dörken B, Hartmann G. Antisense therapy in oncology: new hope for an old idea? Lancet 2001; 358: 489-497. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.